| Anne Kathleen Lehn, PT, DPT | |
|
5950 University Ave Ste 385, West Des Moines, IA 50266-8216 | |
| (515) 875-9706 | |
| (515) 875-9707 |
| Full Name | Anne Kathleen Lehn |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 10 Years |
| Location | 5950 University Ave Ste 385, West Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023427077 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 073106 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Iowa Clinic Pc | 4082513742 | 273 |
News Archive
Nick Chapman, a policy analyst at Policy Cures, writes in a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog about "the results of the latest G-FINDER survey on global funding of [research and development (R&D)] for neglected diseases."
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
The impact of global warming on food prices and hunger could be large over the next 20 years, according to a new Stanford University study. Researchers say that higher temperatures could significantly reduce yields of wheat, rice and maize - dietary staples for tens of millions of poor people who subsist on less than $1 a day.
Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages.
› Verified 5 days ago
| Provider Name | The Iowa Clinic Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1346233178 PECOS PAC ID: 4082513742 Enrollment ID: O20040102000222 |
News Archive
Nick Chapman, a policy analyst at Policy Cures, writes in a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog about "the results of the latest G-FINDER survey on global funding of [research and development (R&D)] for neglected diseases."
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
The impact of global warming on food prices and hunger could be large over the next 20 years, according to a new Stanford University study. Researchers say that higher temperatures could significantly reduce yields of wheat, rice and maize - dietary staples for tens of millions of poor people who subsist on less than $1 a day.
Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anne Kathleen Lehn, PT, DPT Po Box 424, Des Moines, IA 50302-0424 Ph: (515) 875-9925 | Anne Kathleen Lehn, PT, DPT 5950 University Ave Ste 385, West Des Moines, IA 50266-8216 Ph: (515) 875-9706 |
News Archive
Nick Chapman, a policy analyst at Policy Cures, writes in a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog about "the results of the latest G-FINDER survey on global funding of [research and development (R&D)] for neglected diseases."
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
The impact of global warming on food prices and hunger could be large over the next 20 years, according to a new Stanford University study. Researchers say that higher temperatures could significantly reduce yields of wheat, rice and maize - dietary staples for tens of millions of poor people who subsist on less than $1 a day.
Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.
An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages.
› Verified 5 days ago
Ms. Beth Ann Schweizer, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 5700 University Ave, Ste 222, West Des Moines, IA 50266 Phone: 515-221-1621 Fax: 515-221-1626 | |
Julie Angell Earp, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1978 Grand Ave, Suite 45, West Des Moines, IA 50265 Phone: 515-221-2220 Fax: 515-221-2700 | |
Sherry Lynn Merkwan, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 950 Office Park Rd, Suite 100, West Des Moines, IA 50265 Phone: 515-224-0979 Fax: 515-223-3862 | |
Mrs. Jennifer Marie Pitlick, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3200 Westown Pkwy, West Des Moines, IA 50266 Phone: 515-266-1212 | |
Kirsten R Radke, PT DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2001 Westown Pkwy, Ste 107, West Des Moines, IA 50265 Phone: 515-440-3439 Fax: 515-440-3832 | |
Randi V Kass, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1300 50th St Ste 102, West Des Moines, IA 50266 Phone: 515-882-0800 Fax: 515-462-0281 |